The following clinical trials are being conducted:
NSABP B-47: A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer.
SWOG S1007: A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER-2 Negative Breast Cancer with Recurrence Score (RS) of 25 or Less – using Oncotype Dx to determine the Recurrence Score.
The purpose of this study is to find out if the Oncotype DX® Recurrence Score can help decide whether patients should receive chemotherapy or not. This study is being done in patients with lower Recurrence Scores (25 or less).
ALLIANCE A221301: OLANZAPINE FOR THE PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) IN PATIENTS RECEIVING HIGHLY EMETOGENIC CHEMOTHERAPY (HEC): The purpose of this study is to test whether olanzapine (zyprexa) can reduce chemo induced nausea and vomiting.
Oral Anti-Cancer Therapy Research Study - The objective of this dtudy is to assess whether or not patients taking oral anti-cancer therapies (oral antineoplasitc agents) i.e. chemotherapy, targeted biologic therapy, hormone therapy, etc. are adhering to their treatment regimen. If there appears to be a growing trend showing that patients are not adhering to their medication regimen, methods to improve adherence will be studied and implemented.